英国Nxera Pharma和癌症研究公司发起了第二阶段的试验测试,HTL0039732,口服EP4对抗剂,对先进的固态肿瘤进行免疫疗法。 Nxera Pharma and Cancer Research UK launched a Phase 2a trial testing HTL0039732, an oral EP4 antagonist, with immunotherapy for advanced solid tumors.

英国Nxera Pharma和癌症研究公司已开始对HTL0039732进行第二阶段a试验,一名口服EP4对抗者在与免疫疗法相结合时,正在对先进的固态肿瘤进行试验。 Nxera Pharma and Cancer Research UK have started a Phase 2a trial for HTL0039732, an oral EP4 antagonist being tested against advanced solid tumors when combined with immunotherapy. 在早些时候用检查站抑制剂Atezolizumab进行试验时,该药物表现出安全、良好的耐用剂量,并显示出早期的功效迹象。 The drug showed a safe and well-tolerated dose in earlier testing with atezolizumab, a checkpoint inhibitor, and displayed early signs of effectiveness. 试验将招收微型卫星稳定直肠、胃癌、肾癌或前列腺癌患者,并由英国癌症研究中心药物发展中心管理。 The trial will enroll patients with microsatellite stable colorectal, gastric, renal, or prostate cancers and is managed by Cancer Research UK’s Centre for Drug Development. Nxera Pharma公司拥有根据试验结果进一步研制和销售该药物的权利。 Nxera Pharma holds rights to further develop and commercialize the drug based on trial results.